How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - 34 mins ago
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
First quarter 2014 results date notification - May 1, 2014
M2 - Thu Apr 17, 10:18AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), will announce first quarter 2014 earnings on Thursday May 1, 2013.
Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 10:30AM CDT
Abbott Laboratories is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
Pipeline Progress at Coronado Biosciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:20PM CDT
Coronado Biosciences commenced a study evaluating TSO for the treatment of pediatric patients with autism spectrum disorder.
Why ThromboGenics (TBGNF) Stock Is Higher Today
at The Street - Mon Apr 14, 1:30PM CDT
Shares of ThromboGenics (TBGNF) are higher after Novartis (NOV) and Shire (SHPG) were said to be among drugmakers considering offers for the Belgian eye-medicine company.
Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Pipeline Progress at Prothena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 11:00AM CDT
Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.
Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).
Roche Acquires IQuum - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:35PM CDT
In order to strengthen its diagnostics business, Roche announced that it has acquired privately held IQuum, Inc. for $275 million in upfront cash.
Genocea Appoints Jonathan Poole as Chief Financial Officer
Business Wire - Mon Apr 07, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the appointment of Jonathan Poole to the position of chief financial officer. Mr. Poole joins Genocea from Shire plc (NASDAQ: SHPG).
BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.
Fast-Track Status for Tetraphase Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:05PM CDT
Shares of Tetraphase Pharma were up 2.5% after the company received Fast Track designation from FDA for its lead antibiotic candidate, eravacycline.
Positive Data on Forest Labs/Gedeon's Cariprazine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:40PM CDT
Forest Labs and partner Gedeon Richter's antipsychotic candidate, cariprazine, met the primary endpoint in a phase IIb study.
Positive News for Novartis' LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:27PM CDT
Novartis received positive news when the Data Monitoring Committee unanimously recommended the early closure of the phase III study, PARADIGM-HF, on candidate LCZ696.
J&J to Sell Ortho Clinical Diagnostics Biz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 12:50PM CDT
The $4 billion deal is expected to go through in mid-14.
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Adderall(TM) and Kid Rock to Launch New Energy Drink "Adderall Up!"
Marketwire - Tue Apr 01, 6:01AM CDT
Disclaimer: The following release is for April Fool's Day: